<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02070757</url>
  </required_header>
  <id_info>
    <org_study_id>7625A-008</org_study_id>
    <secondary_id>CXA-NP-11-04</secondary_id>
    <secondary_id>163338</secondary_id>
    <nct_id>NCT02070757</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia (MK-7625A-008)</brief_title>
  <acronym>ASPECT-NP</acronym>
  <official_title>A Prospective, Randomized, Double-Blind, Multicenter, Phase 3 Study to Assess the Safety and Efficacy of Intravenous Ceftolozane/Tazobactam Compared With Meropenem in Adult Patients With Ventilated Nosocomial Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cubist Pharmaceuticals LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cubist Pharmaceuticals LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 3, multicenter, prospective, randomized study of intravenous (IV)
      ceftolozane/tazobactam vs. IV meropenem in the treatment of adult participants with either
      ventilator-associated bacterial pneumonia (VABP) or ventilated hospital-acquired bacterial
      pneumonia (HABP).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 23, 2014</start_date>
  <completion_date type="Anticipated">June 19, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 28, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All Cause Mortality</measure>
    <time_frame>Day 28</time_frame>
    <description>Intent-to-Treat (ITT) population</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical response rates at the TOC visit (ceftolozane/tazobactam versus meropenem) in the subset of subjects who had P. aeruginosa from the baseline lower respiratory tract culture</measure>
    <time_frame>TOC is 7-14 days after EOT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 28 all-cause mortality rates of participants in the ceftolozane/tazobactam versus meropenem arms in the Microbiological Intent-to-Treat (mITT) population</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response rates of ceftolozane/tazobactam versus meropenem in adult participants with ventilated nosocomial pneumonia (VNP) in the Microbiological Intent-to-Treat (mITT) population</measure>
    <time_frame>This will be assessed at the Test-of-cure (TOC) visit which is 7 to 14 days after the End of Therapy (EOT) visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response rates of ceftolozane/tazobactam versus meropenem in adult participants with VNP in the Intent-to-Treat (ITT) population</measure>
    <time_frame>This will be assessed at the Test-of-cure (TOC) visit which is 7 to 14 days after the End of Therapy (EOT) visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response rates of ceftolozane/tazobactam versus meropenem in adult participants with VNP in the Clinically Evaluable (CE) population</measure>
    <time_frame>This will be assessed at the Test-of-cure (TOC) visit which is 7 to 14 days after the End of Therapy (EOT) visit</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">726</enrollment>
  <condition>Nosocomial Pneumonia</condition>
  <arm_group>
    <arm_group_label>Ceftolozane/tazobactam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ceftolozane/tazobactam IV 3000 mg (comprising 2000 mg ceftolozane and 1000 mg tazobactam) every 8 hours for 8-14 days, or 14 days for Pseudomonas aeruginosa.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>meropenem</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>meropenem IV 1000 mg every 8 hours for 8-14 days, or 14 for Pseudomonas aeruginosa</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ceftolozane/tazobactam</intervention_name>
    <description>Ceftolozane/tazobactam is an antibacterial consisting of a co-formulation of ceftolozane, a novel antipseudomonal cephalosporin and tazobactam, a well-established beta(Î²)-lactamase inhibitor (BLI) being developed for the treatment of serious bacterial infections.</description>
    <arm_group_label>Ceftolozane/tazobactam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meropenem</intervention_name>
    <description>Meropenem is a broad spectrum injectable antibiotic widely used to treat serious infections such as ventilator-associated bacterial pneumonia and hospital-acquired bacterial pneumonia.</description>
    <arm_group_label>meropenem</arm_group_label>
    <other_name>Merofit</other_name>
    <other_name>Monan</other_name>
    <other_name>Meronem</other_name>
    <other_name>Merrem</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Adult participants diagnosed with either VABP or ventilated HABP requiring IV
             antibiotic therapy;

          -  Intubated and on mechanical ventilation at the time of randomization;

          -  New or progressive infiltrate on chest radiography consistent with pneumonia;

          -  Presence of clinical criteria consistent with a diagnosis of ventilated nosocomial
             pneumonia.

        Key Exclusion Criteria:

          -  History of moderate or severe hypersensitivity reactions to beta-lactam antibiotics;

          -  Prior non-study antibiotics for &gt; 24 hours;

          -  Gram stain of lower respiratory tract specimen showing only gram positive bacteria;

          -  Active immunosuppression;

          -  End-stage renal disease or requirement for dialysis;

          -  Expected survival &lt; 72 hours;

          -  Severe confounding respiratory condition (i.e., chest trauma with paradoxical
             respiration);

          -  Known or suspected community-acquired bacterial pneumonia.

          -  Anticipated concomitant use of any of the following medications during the course of
             study therapy: valproic acid or divalproex sodium. Anticipated concomitant use of
             serotonin re-uptake inhibitors, tricyclic antidepressants, or serotonin 5-HT1 receptor
             agonists (triptans), meperidine, or buspirone during the course of linezolid
             treatment.

          -  Receipt of a monoamine oxidase inhibitor within 14 days prior to the first dose of
             study drug or anticipated concomitant use during the course of linezolid therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>Croatia</country>
    <country>Czech Republic</country>
    <country>Czechia</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Guatemala</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Latvia</country>
    <country>Lebanon</country>
    <country>New Zealand</country>
    <country>Philippines</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Xiao AJ, Miller BW, Huntington JA, Nicolau DP. Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia. J Clin Pharmacol. 2016 Jan;56(1):56-66. doi: 10.1002/jcph.566. Epub 2015 Aug 25.</citation>
    <PMID>26096377</PMID>
  </results_reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2014</study_first_submitted>
  <study_first_submitted_qc>February 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2014</study_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ventilator-associated bacterial pneumonia</keyword>
  <keyword>Hospital-acquired bacterial pneumonia</keyword>
  <keyword>Pneumonia</keyword>
  <keyword>Lung Diseases</keyword>
  <keyword>Respiratory Tract Diseases</keyword>
  <keyword>Respiratory Tract Infections</keyword>
  <keyword>Infection</keyword>
  <keyword>Ventilator-Induced Lung Injury</keyword>
  <keyword>Lung Injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meropenem</mesh_term>
    <mesh_term>Thienamycins</mesh_term>
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Penicillanic Acid</mesh_term>
    <mesh_term>Cephalosporins</mesh_term>
    <mesh_term>Ceftolozane, tazobactam drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

